Drug Profile
Research programme: psychiatric disorder therapeutics - Exscientia/Sumitomo Pharma America
Latest Information Update: 22 Jul 2023
Price :
$50
*
At a glance
- Originator Exscientia; Sunovion Pharmaceuticals
- Developer Exscientia; Sumitomo Pharma America
- Class Small molecules
- Mechanism of Action G protein-coupled receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psychiatric disorders
Most Recent Events
- 28 May 2023 No recent reports of development identified for research development in Psychiatric-disorders in United Kingdom
- 12 May 2021 Research development in Psychiatric disorders is still ongoing in United Kingdom (Sumitomo Dainippon Pharma's pipeline, May 2021)
- 28 Dec 2018 No recent reports of development identified for research development in Psychiatric-disorders in United Kingdom